Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción WHWK?
El precio actual de WHWK es de $2.53, ha decreased un 4.88% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Whitehawk Therapeutics Inc?
Whitehawk Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Whitehawk Therapeutics Inc?
La capitalización bursátil actual de Whitehawk Therapeutics Inc es $119.2M
¿Es Whitehawk Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Whitehawk Therapeutics Inc, incluyendo 0 fuerte compra, 0 compra, 5 mantener, 1 venta, y 0 fuerte venta
